Oral Alzheimer's Drug Buntanetap Shows Cognitive Gains and Biomarker Shifts in Phase 2/3 Trial
Annovis's buntanetap reduced tau and neuroinflammation markers while improving cognition in mild Alzheimer's patients across a 12-week trial.
Summary
Annovis Bio has published peer-reviewed results for buntanetap, an oral Alzheimer's drug, in Nature NPJ Dementia. The 12-week randomized controlled trial tested three doses in 351 patients with mild to moderate Alzheimer's disease. The 30 mg dose produced statistically significant cognitive improvements — measured by the ADAS-Cog11 scale — specifically in patients with confirmed pTau217 biomarker positivity and mild disease. Beyond cognition, the drug reduced levels of toxic proteins like TDP-43 and tau, and lowered neuroinflammation markers including IL-6 and IFN-γ. Neurofilament light chain, a marker of nerve damage, also decreased. The drug was well tolerated across all doses, ages, sexes, and genetic risk profiles including ApoE4 carriers. A larger pivotal Phase 3 trial is now 80% enrolled, targeting early Alzheimer's patients over 6 and 18 months.
Detailed Summary
Alzheimer's disease remains one of the most challenging frontiers in longevity medicine, and a new peer-reviewed publication from Annovis Bio offers a meaningful signal that an oral, once-daily drug called buntanetap may slow its progression. The results, published in Nature NPJ Dementia, come from a randomized, double-blind, placebo-controlled Phase 2/3 trial — the gold standard in clinical research design.
The trial enrolled 351 patients with mild to moderate Alzheimer's disease and tested three doses — 7.5 mg, 15 mg, and 30 mg — over 12 weeks. The most compelling results emerged in a biomarker-defined subgroup: patients who tested positive for pTau217, a blood-based marker of Alzheimer's pathology, and who had mild disease (MMSE scores of 21–24). In this group, the 30 mg dose produced statistically significant, dose-dependent improvements on the ADAS-Cog11 cognitive scale.
Beyond cognition, buntanetap appeared to reduce several neurotoxic proteins, including TDP-43 and tau, and lowered neuroinflammation markers such as IL-5, IL-6, S100A12, IFN-γ, and IGF1R. Crucially, neurofilament light chain — a blood biomarker reflecting neuronal damage — also declined, which Annovis interprets as evidence of potential disease-modifying activity rather than mere symptom masking.
The drug was safe and well tolerated across all doses, disease stages, ages, BMI ranges, sexes, ethnicities, and ApoE4 genetic risk carriers — a notably broad tolerability profile. This matters because ApoE4 carriers face significantly elevated Alzheimer's risk and have historically shown differential responses to some therapies.
Important caveats apply. The 12-week duration is short for a disease measured in years, and the key cognitive benefits were confined to a biomarker-positive, mild-disease subgroup. A pivotal Phase 3 trial now 80% enrolled will test 6- and 18-month outcomes in early Alzheimer's patients — results from that study will be far more definitive for clinical translation.
Key Findings
- 30 mg buntanetap improved cognition on ADAS-Cog11 in pTau217-positive mild Alzheimer's patients over 12 weeks
- Blood biomarkers of neuroinflammation including IL-6 and IFN-γ were reduced, suggesting possible disease-modifying effects
- Neurofilament light chain, a marker of neuronal damage, decreased across treatment groups
- Drug was well tolerated across all doses, ages, sexes, and ApoE4 genetic risk carriers
- Pivotal Phase 3 trial targeting early Alzheimer's is approximately 80% enrolled with 18-month outcomes planned
Methodology
This is a news report summarizing a peer-reviewed Phase 2/3 randomized controlled trial published in Nature NPJ Dementia, a credible journal. The trial (NCT05686044) used a double-blind, placebo-controlled design with 351 participants across three dose arms. Evidence quality is high for this stage, though findings are based on a subgroup analysis and a short 12-week window.
Study Limitations
The primary cognitive benefit was observed in a biomarker-defined subgroup, limiting generalizability to all Alzheimer's patients. The 12-week trial duration is insufficient to assess long-term disease modification or safety. Results are reported via a company-issued summary; readers should consult the primary Nature NPJ Dementia publication for full statistical details and effect sizes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.